Bli medlem
Bli medlem

Du är här


Oxford Immunotec: Oxford Immunotec Announces CE Mark Approval for T-SPOT.CMV Test

Product to be Featured at a Symposium at the European Congress of Clinical
Microbiology and Infectious Disease

OXFORD, UK and MARLBOROUGH, Mass., April 27, 2015 (GLOBE NEWSWIRE) -- Oxford
Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics
company focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions, today announced that it had gained
CE Marking for its T-SPOT®

"We are pleased our T-SPOT.CMV
test gained CE Mark approval earlier than our expectations," said Dr. Peter
Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "While we are
enthusiastic about the potential clinical and economic value T-SPOT.CMV
may provide in transplant medicine we are taking a measured approach to market
introduction as we await the results of our PROTECT and REACT clinical
trials. We continue to expect full commercial launch in the second half of

T cell immunity against cytomegalovirus (CMV) is a factor in controlling viral
latency and susceptibility to CMV disease. CMV can affect individuals with
weaknesses in their T cell response and it is therefore an important and
common cause of morbidity and mortality in solid organ and hematopoietic stem
cell transplant recipients. The T-SPOT.CMV
test measures the strength of T cell responses to CMV specific antigens. The
test has the potential to assist clinicians with monitoring anti-viral
prophylaxis and evaluating patients at risk from CMV disease.

"Measuring T Cell Mediated CMV / TB Response with ELISPOT Technology" is the
subject of an integrated symposium that will be held tomorrow, April 28, at
the European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID) meeting in Copenhagen, Denmark. Investigators Dr. Roy Chemaly and
Dr. Oriol Bestard Matamoros will be presenting their experience using the
T-SPOT technology for immune monitoring and T cell response to CMV in
hematopoietic stem cell transplant patients and solid organ transplant

test leverages Oxford Immunotec's proprietary T-SPOT technology platform, and
is the first in a series of planned new products intended to help transplant
patients and physicians manage immune regulated conditions. The test is
available now as a CE-marked kit in the EU, and will soon be available in the
UK as a testing service from our UK ODL laboratory. T-SPOT.CMV
is also available in the US as a Laboratory Developed Test from the Company's
CLIA-certified and CAP accredited ODL service laboratory1.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions. The Company's first product is the
test, which is used to test for tuberculosis infection. The T-SPOT.TB
test has been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The T-SPOT.CMV
test is the Company's second product and the first in a series of products
intended for the transplantation market. Overall, the Company has six active
development programs, each of which leverages our T cell and innate immune
measuring technology. The Company is headquartered near Oxford, UK and in
Marlborough, MA. Additional information can be found

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

test is pending approval in California, New York and Florida


For Media Inquiries:

Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796

For Investor Inquiries:

Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.